Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer ...

Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high ...

Fertility preservation becomes crucial for reproductive-age cancer patients, emphasizing timely intervention and ...

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced ...

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, ...

Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a ...